GSK, Vir partner on infectious diseases therapies

By The Science Advisory Board staff writers

February 17, 2021 -- GlaskoSmithKline (GSK) and Vir Biotechnology have signed a deal to research and develop new therapies for influenza and other respiratory viruses.

GSK has been granted the exclusive rights to collaborate with Vir on the development of potential monoclonal antibodies (mAbs) for the prevention or treatment of influenza. These include VIR-2482, an intramuscularly administered, investigational mAb, designed as a universal prophylactic for influenza A. GSK also will have the exclusive option to co-develop VIR-2482 after Vir completes and reports phase II trial outcomes, and it will share development costs on the development of all other influenza mAbs.

Additionally, they will collaborate to develop up to three neutralizing mAbs to target noninfluenza pathogens during a three-year research period.

This deal builds upon their 2020 agreement to research and develop therapies for coronaviruses. Under the agreement, GSK will make an upfront payment of $225 million and an equity investment in Vir of $120 million. If GSK exercises its option to co-develop VIR-2482 past phase II, it will pay an option fee of $300 million. GSK will also pay Vir up to $200 million based on the successful delivery of predefined regulatory milestones.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here